<<

American Association of Feline Practitioners 2006 Feline Guidelines. Summary: Vaccination in General Practice

Primary Series- Primary Series- Adolescent/ Booster Comments (< 16 weeks) Adult (> 16 weeks) Panleukopenia Begin as early as 6 2 doses, 3 to 4 A single dose is given 1 Core (FPV) /Feline weeks of age, then weeks apart year following the last • Killed are preferred for use in Herpesvirus-1 and Feline every 3-4 weeks until dose of the initial series, pregnant (and only if absolutely Calicivirus (FHV-1/FCV) 16 weeks of age. then no more frequently necessary) and in FeLV and/or FIV infected Injectable: than every 3 years. cats, especially those showing evidence of • MLV, non- . adjuvanted • Killed panleukopenia vaccines should be used • Killed, adjuvantedi in kittens less than 4 weeks of age. • Killed, non- • All kittens and cats should receive at least one adjuvanted injectable panleukopenia injection.

Intranasal • MLV, non- . adjuvanted

Rabiese Administer a single Administer 2 doses, Annual booster is Core Injectable: dose as early as 8 or 12 months apart. required. • In States and municipalities where feline • virus- 12 weeks of age vaccination is required, vectored depending on the Vs. Every 3 years or as must follow applicable statutes. recombinant product label. required by State or local • Booster vaccination with a 1-year rabies (rRabies), non- Revaccinate 1 year ordinance for 3-year vaccine is only appropriate in States and adjuvanted later. municipalities where permitted by law. • 1-year killed, • Any rabies vaccine can be used for adjuvanteda revaccination, even if the product is not the • 3-Year killed, same brand or type of product previously adjuvanteda administered. • No laboratory or epidemiologic data exist to support the annual or biennial administration of 3-year vaccines following the initial series.

Feline Virus Administer an initial 2 doses, 3 to 4 When indicated, a single Non-Core (FeLV) dose as early as 8 – 12 weeks apart dose is given 1 year • FeLV vaccination is highly recommended Transdermal: weeks of age, following the last dose of for all kittens. • Canarypox virus- depending on product; the initial series, then • Booster inoculation is recommended only in vectored a second dose should annually in cats cats considered to be at risk of exposure. ii recombinant be administered 3-4 determined to have • In the United States, the 0.25 ml rFeLV (rFeLV), non- weeks later. sustained risk of vaccine dose may only be administered via f adjuvanted exposure. the manufacturer’s transdermal administration system.iii Injectable • Only FeLV negative cats should be • Or Killed, vaccinated; FeLV testing prior to vaccine adjuvanted administration is recommended. • Cats should be tested for FeLV before their initial vaccination and when there is a possibility that they have been exposed to FeLV since they were last vaccinated.

When indicated, 3 When indicated, 3 When indicated, a single Non-Core Feline Immunodeficiency doses are required: doses are required: dose is given 1 year • FIV vaccine should be restricted to cats at Virus (FIV) following the last dose of high risk of infection.iv The initial dose is Each dose is the initial series, then • Vaccination induces production of Injectable: administered as early administered 2-3 annually in cats indistinguishable from those developed in as 8 weeks of age; 2 weeks apart. determined to have response to FIV infection, and interferes with • Killed, adjuvanteda subsequent doses sustained risk of all -based FIV diagnostic tests for at h should be administered exposure. least a year following vaccination. at an interval of 2-3 • Cats with positive FIV antibody assay results weeks. may have antibodies as a result of vaccination, infection, or both. • FIV antibodies are passed from vaccinated queens to their kittens in . Colostrum-derived antibodies interfere with FIV diagnosis past the age of weaning in the majority of kittens, but this interference appears to wane by 12 weeks of age. • Cats should test FIV-antibody negative immediately prior to vaccination. • Permanent identification of vaccinated cats (e.g., using a microchip) will help clarify vaccination status, but will not indicate that such cats are free of infection. • This vaccine has been shown to provide protection from some, but not all, strains of FIV.

Feline Infectious If administered, give a If administered, Annual booster is Not Generally Recommended Peritonitis (FIP) single dose as early as give 2 doses, 3-4 recommended by the • According to the limited studies available, only • MLV, non- 16 weeks of age, and a weeks apart. manufacturer. cats known to be feline antibody adjuvanted second dose 3-4 weeks negative at the time of vaccination are likely to later. develop some level of protection. • Intranasal • Vaccination of cats living within households in which FIP is known to exist or cats that are known to be antibody positive is not recommended.

Chlamydophila felis Administer the initial Administer 2 doses, Annual booster is Non-Core • Avirulent live, non- dose as early as 9 3-4 weeks apart. indicated for cats with • Vaccination reserved as part of a control adjuvanted weeks of age; a second sustained exposure risk. regime for cats in multiple-cats environments • Or killed, dose is administered 3- where associated with clinical adjuvanted 4 weeks later. disease have been confirmed. • Inadvertent conjunctival inoculation of vaccine • Injectable has been reported to cause clinical signs of infection.

Bordetella Administer a single Administer a single Annual booster is Non-Core bronchiseptica dose intranasally as dose intranasally indicated for cats with • Vaccination may be considered in cases • Avirulent live, non- early as 8 weeks of sustained risk. where cats are likely to be at specific risk of adjuvanted age. infection.v • Do not give this product parenterally, as It • Intranasal may cause a severe adverse reaction that can cause death of the . Feline Giardia Administer a single 2 doses, 2-4 weeks Annual booster is Not Generally Recommended • Killed, adjuvanteda dose at 8 weeks of age; apart. recommended by the • There are insufficient studies available to a second dose is manufacturer. support the role of Giardia vaccination in • Injectable administered 2-4 weeks preventing clinical disease in cats. later. • Whether the Giardia vaccine is an effective therapeutic agent in naturally infected cats is currently unknown.

i Injectable adjuvanted vaccines have been associated with local inflammatory reactions at injection sites, with the degree of varying among products. The potential role of local inflammatory reactions in the genesis of vaccine-associated sarcomas remains controversial. ii Cats allowed outdoors, cats residing in open multiple-cat environments, cat living with FeLV-infected cats, and cats residing in households with cats of unknown FeLV- infection status or where introduction of new cats is common. Booster inoculation is not generally recommended for cats housed strictly indoors. iii A recombinant FeLV vaccine available in Europe is designed to be administered by subcutaneous injection; this product differs from the one licensed in the United States. iv For example, outdoor fighting cats and FIV-uninfected cats living with FIV-infected cats. v For example, prior to confinement in multiple-cat environments such as rescue shelters, boarding facilities or catteries where bordetellosis has been confirmed.